Anzic Mitja, Marinko Tanja
Division of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
J Breast Cancer. 2020 Oct;23(5):449-459. doi: 10.4048/jbc.2020.23.e48.
Breast cancer is the most common malignancy among women. Therefore, it is of paramount importance to study the adverse effects of oncological treatment of breast cancer, with one of adverse effects being pulmonary fibrosis (PF). PF is an irreversible condition and can significantly reduce the quality of life. Following lumpectomy, radiotherapy is the standard adjuvant treatment for breast cancer. Additionally, hormone receptor-positive breast cancers are treated with adjuvant hormonal therapy. While radiotherapy is one of the known causes of PF, the effect of hormone therapy on its development is not well-defined. Some studies have shown that the concomitant administration of endocrine therapy, primarily tamoxifen, and irradiation may potentiate the development of PF. However, guidelines regarding the timing of hormone therapy administration with respect to adjuvant radiotherapy are not clearly defined. This review aims to provide a comprehensive overview of the available information regarding the effect of hormone therapy and its timing of administration with respect to adjuvant radiotherapy on the incidence of PF.
乳腺癌是女性中最常见的恶性肿瘤。因此，研究乳腺癌肿瘤治疗的不良反应至关重要，其中一种不良反应是肺纤维化（PF）。PF是一种不可逆的病症，会显著降低生活质量。乳房肿瘤切除术后，放射治疗是乳腺癌的标准辅助治疗方法。此外，激素受体阳性的乳腺癌采用辅助激素疗法治疗。虽然放射治疗是已知的PF病因之一，但激素疗法对其发展的影响尚不明确。一些研究表明，内分泌治疗（主要是他莫昔芬）与放射治疗同时使用可能会加剧PF的发展。然而，关于辅助放疗时激素疗法给药时间的指南尚未明确界定。本综述旨在全面概述有关激素疗法及其在辅助放疗时的给药时间对PF发生率影响的现有信息。
